Patents

Abstract: The invention describes compositions and methods for the management of hyperproliferative skin conditions such as psoriasis. The preferential composition contains a natural leukotriene inhibitor selected from Boswellia serrata gum resin, its extractives, isolates or derivatives in combination with a bioavailable organic selenium nutritional supplement. These compositions are administered orally and topically to the individual human or animal in need of treatment at optimal levels to manifest the desired benefits, with no untoward side effects.

Abstract: The invention describes compositions and methods for the management of hyperproIiferative skin conditions such as psoriasis. The preferential composition contains a natural leukotriene inhibitor selected from Boswellia serrata gum resin, its extractives, isolates or derivatives in combination with a bioavailable organic selenium nutritional supplement. These compositions are administered orally and topically to the individual human or animal in need of treatment at optimal levels to manifest the desired benefits, with no untoward side effects.

Abstract: The present invention provides a composition for down-regulating pro-inflammatory markers. The composition comprises boswellic acid fraction and polysaccharide fraction obtained from Boswellia species at specific concentrations showing enhancement in their activity as compared to boswellic acid fraction and the polysaccharide fraction alone. The invention further comprises the use of polysaccharide fraction individually or in combination with boswellic acid fraction for the inhibition of PGE2.

Abstract: The present invention provides a composition for down-regulating pro-inflammatory markers. The composition comprises boswellic acid fraction and polysaccharide fraction obtained from Boswellia species at specific concentrations showing enhancement in their activity as compared to boswellic acid fraction and the polysaccharide fraction alone. The invention further comprises the use of polysaccharide fraction individually or in combination with boswellic acid fraction for the inhibition of PGE2.

Abstract: The present invention provides the use of a composition for pro-inflammatory markers. The composition comprising polysaccharide fraction obtained from Boswellia species for down-regulating/inhibiting PGE2

Abstract: The present invention relates to a process of preparing a synergistic composition for treating hyperproliferative dermatological conditions through oral and/or topical administration, said process comprising steps of (a) obtaining Boswellia gum extract containing boswellic acids of concentration ranging between 50 mg to 500mg; (b) obtaining selenium of concentration ranging between 10 mg to 200 mg; (c) mixing the Boswellia gum extract of step (a) with selenium of step (b), optionally along with pharmaceutically acceptable excipients; and (d) obtaining the synergistic composition for treatment of hyperproliferative dermatological conditions.